The development of a side effect risk assessment tool (ASyMS©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy

Roma Maguire, Julie Cowie, Clare Leadbetter, Kathryn McCall, Kevin Swingler, Lisa McCann, Nora Kearney

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Patients with breast cancer receiving chemotherapy are at risk of developing toxicities which can be severe or life threatening. The aim of this study was to develop and test a side effect risk modeling tool (ASyMS ©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. The study was conducted in two phases. Phase 1 entailed the development of the ASyMS©-SERAT tool using a secondary data set and in collaboration with an expert group of clinicians and an advisory group of patients. In phase 2, the predictive accuracy of the tool was measured using a prospective data set of 24 patients with breast cancer undergoing adjuvant chemotherapy. A high level of accuracy was reported for four of the six symptoms measured (>70%) supporting the future development and application of ASyMS©-SERAT in the prediction of chemotherapy-related toxicity. For patients, such information can be used to target information on side effects that they are likely to experience thereby facilitating the provision of tailored information based on their individual needs. For clinicians, knowing the likelihood of potential side effects can assist them in identifying patients who are at greater risk of developing certain toxicities, facilitating more targeted and cost-effective interventions.

LanguageEnglish
Pages27-40
Number of pages14
JournalJournal of Research in Nursing
Volume14
Issue number1
DOIs
Publication statusPublished - 1 Jan 2009
Externally publishedYes

Fingerprint

Adjuvant Chemotherapy
Breast Neoplasms
Drug Therapy
Costs and Cost Analysis

Keywords

  • breast cancer
  • chemotherapy
  • predictive risk modelling
  • symptoms

Cite this

@article{c9793e40f4744e9883e607a8d35f54d5,
title = "The development of a side effect risk assessment tool (ASyMS{\circledC}-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy",
abstract = "Patients with breast cancer receiving chemotherapy are at risk of developing toxicities which can be severe or life threatening. The aim of this study was to develop and test a side effect risk modeling tool (ASyMS {\circledC}-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. The study was conducted in two phases. Phase 1 entailed the development of the ASyMS{\circledC}-SERAT tool using a secondary data set and in collaboration with an expert group of clinicians and an advisory group of patients. In phase 2, the predictive accuracy of the tool was measured using a prospective data set of 24 patients with breast cancer undergoing adjuvant chemotherapy. A high level of accuracy was reported for four of the six symptoms measured (>70{\%}) supporting the future development and application of ASyMS{\circledC}-SERAT in the prediction of chemotherapy-related toxicity. For patients, such information can be used to target information on side effects that they are likely to experience thereby facilitating the provision of tailored information based on their individual needs. For clinicians, knowing the likelihood of potential side effects can assist them in identifying patients who are at greater risk of developing certain toxicities, facilitating more targeted and cost-effective interventions.",
keywords = "breast cancer, chemotherapy, predictive risk modelling, symptoms",
author = "Roma Maguire and Julie Cowie and Clare Leadbetter and Kathryn McCall and Kevin Swingler and Lisa McCann and Nora Kearney",
year = "2009",
month = "1",
day = "1",
doi = "10.1177/1744987108099235",
language = "English",
volume = "14",
pages = "27--40",
journal = "Journal of Research in Nursing",
issn = "1744-9871",
number = "1",

}

The development of a side effect risk assessment tool (ASyMS©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. / Maguire, Roma; Cowie, Julie; Leadbetter, Clare; McCall, Kathryn; Swingler, Kevin; McCann, Lisa; Kearney, Nora.

In: Journal of Research in Nursing, Vol. 14, No. 1, 01.01.2009, p. 27-40.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The development of a side effect risk assessment tool (ASyMS©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy

AU - Maguire, Roma

AU - Cowie, Julie

AU - Leadbetter, Clare

AU - McCall, Kathryn

AU - Swingler, Kevin

AU - McCann, Lisa

AU - Kearney, Nora

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Patients with breast cancer receiving chemotherapy are at risk of developing toxicities which can be severe or life threatening. The aim of this study was to develop and test a side effect risk modeling tool (ASyMS ©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. The study was conducted in two phases. Phase 1 entailed the development of the ASyMS©-SERAT tool using a secondary data set and in collaboration with an expert group of clinicians and an advisory group of patients. In phase 2, the predictive accuracy of the tool was measured using a prospective data set of 24 patients with breast cancer undergoing adjuvant chemotherapy. A high level of accuracy was reported for four of the six symptoms measured (>70%) supporting the future development and application of ASyMS©-SERAT in the prediction of chemotherapy-related toxicity. For patients, such information can be used to target information on side effects that they are likely to experience thereby facilitating the provision of tailored information based on their individual needs. For clinicians, knowing the likelihood of potential side effects can assist them in identifying patients who are at greater risk of developing certain toxicities, facilitating more targeted and cost-effective interventions.

AB - Patients with breast cancer receiving chemotherapy are at risk of developing toxicities which can be severe or life threatening. The aim of this study was to develop and test a side effect risk modeling tool (ASyMS ©-SERAT) for use in patients with breast cancer undergoing adjuvant chemotherapy. The study was conducted in two phases. Phase 1 entailed the development of the ASyMS©-SERAT tool using a secondary data set and in collaboration with an expert group of clinicians and an advisory group of patients. In phase 2, the predictive accuracy of the tool was measured using a prospective data set of 24 patients with breast cancer undergoing adjuvant chemotherapy. A high level of accuracy was reported for four of the six symptoms measured (>70%) supporting the future development and application of ASyMS©-SERAT in the prediction of chemotherapy-related toxicity. For patients, such information can be used to target information on side effects that they are likely to experience thereby facilitating the provision of tailored information based on their individual needs. For clinicians, knowing the likelihood of potential side effects can assist them in identifying patients who are at greater risk of developing certain toxicities, facilitating more targeted and cost-effective interventions.

KW - breast cancer

KW - chemotherapy

KW - predictive risk modelling

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=58149503651&partnerID=8YFLogxK

U2 - 10.1177/1744987108099235

DO - 10.1177/1744987108099235

M3 - Article

VL - 14

SP - 27

EP - 40

JO - Journal of Research in Nursing

T2 - Journal of Research in Nursing

JF - Journal of Research in Nursing

SN - 1744-9871

IS - 1

ER -